---
title: "Novartis India (EVONILE) Share Price, Financials & Research"
symbol: "EVONILE"
company: "Novartis India Ltd"
canonical: "https://tapetide.com/stocks/EVONILE"
isin: "INE234A01025"
nse_symbol: "EVONILE"
bse_code: "500672"
sector: "Healthcare"
industry: "Pharmaceuticals"
generated_at: "2026-11-05T01:34:40.411Z"
---

# Novartis India (EVONILE)

Canonical page: https://tapetide.com/stocks/EVONILE

## Key Facts

- **Price:** ₹1,714.30 as of 4 Nov 2026, 15:53 IST
- **P/E (TTM):** 43.28 as of 4 Nov 2026
- **Revenue, Jun 2026 quarter:** ₹103.8 Cr, against ₹87.6 Cr in Jun 2025 (+18.49% year on year)
- **Net profit, Jun 2026 quarter:** ₹32.2 Cr, against ₹27.6 Cr in Jun 2025 (+16.67% year on year)
- **Promoter holding:** 70.68% in Sep 2026, unchanged from Jun 2026
- **Tapetide Score:** 55/100, Good band as of 12 Oct 2026

## Company

- **NSE symbol:** EVONILE
- **BSE code:** 500672
- **ISIN:** INE234A01025
- **Macro sector:** Healthcare
- **Sector:** Healthcare
- **Industry:** Pharmaceuticals
- **In the F&O segment:** No

## Latest Price

- **Price:** ₹1,714.30
- **Change:** No trade today
- **Previous Close:** ₹1,714.30
- **As of:** 4 Nov 2026, 15:53 IST

## Key Fundamentals

Price-based figures as of 4 Nov 2026, 15:53 IST · EPS basis: Standalone · TTM.

- **ROCE:** 16.30%
- **Debt to Equity:** 0.00
- **EPS (TTM):** ₹39.61
- **Book Value:** ₹331.23
- **P/E (TTM):** 43.28
- **P/B:** 5.18
- **ROE:** 11.60%
- **Dividend Yield:** 1.45%
- **EBITDA:** ₹133 Cr
- **52W High:** ₹2,588.80
- **52W Low:** ₹909.70

## Peer Comparison

Classification: Healthcare › Pharmaceuticals

| Company | Price | P/E | Market Cap | P/B | Div Yield | ROE | ROCE | Sales TTM | Net Profit TTM |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| [Sun Pharmaceutical Industries Ltd (SUNPHARMA)](https://tapetide.com/stocks/SUNPHARMA) | ₹1,773.40 | 38.81 | ₹4,29,049 Cr | 4.77 | 0.90% | 16.00% | 20.50% | ₹61,631 Cr | ₹10,987 Cr |
| [Divis Laboratories Ltd (DIVISLAB)](https://tapetide.com/stocks/DIVISLAB) | ₹10,037.50 | 91.10 | ₹2,65,269 Cr | 15.90 | 0.30% | 16.50% | 22.00% | ₹11,230 Cr | ₹2,925 Cr |
| [Torrent Pharmaceuticals Ltd (TORNTPHARM)](https://tapetide.com/stocks/TORNTPHARM) | ₹4,738.50 | 78.61 | ₹1,77,061 Cr | 9.81 | 0.82% | 27.40% | 15.20% | ₹17,400 Cr | ₹2,099 Cr |
| [Zydus Lifesciences Ltd (ZYDUSLIFE)](https://tapetide.com/stocks/ZYDUSLIFE) | ₹1,188.10 | 26.44 | ₹1,25,446 Cr | 4.37 | 0.08% | 21.20% | 21.10% | ₹28,592 Cr | ₹4,593 Cr |
| [Laurus Labs Ltd (LAURUSLABS)](https://tapetide.com/stocks/LAURUSLABS) | ₹2,323.80 | 114.81 | ₹1,25,228 Cr | 20.72 | 0.04% | 18.30% | 17.80% | ₹7,270 Cr | ₹1,090 Cr |
| [Dr Reddys Laboratories Ltd (DRREDDY)](https://tapetide.com/stocks/DRREDDY) | ₹1,374.00 | 35.59 | ₹1,14,543 Cr | 2.96 | 0.58% | 11.20% | 13.00% | ₹33,228 Cr | ₹3,184 Cr |
| [Cipla Ltd (CIPLA)](https://tapetide.com/stocks/CIPLA) | ₹1,402.00 | 33.59 | ₹1,12,454 Cr | 3.20 | 0.93% | 11.60% | 15.50% | ₹28,324 Cr | ₹3,356 Cr |
| [Novartis India Ltd (EVONILE)](https://tapetide.com/stocks/EVONILE) (this company) | ₹1,714.30 | 43.28 | ₹4,257 Cr | 5.18 | 1.45% | 11.60% | 16.30% | ₹371 Cr | ₹97 Cr |
| Median of 8 companies | ₹1,743.85 | 41.05 | ₹1,25,337 Cr | 4.98 | 0.70% | 16.25% | 17.05% | ₹22,862 Cr | ₹3,055 Cr |

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company. 1 company is not shown because they are not listed on an exchange we cover.

## Tapetide Score

Data-driven rating, 0–100, as of 12 Oct 2026.

- **Score:** 55/100 (Good)
- **Data confidence:** 100/100

### Category scores

| Category | Score | Band | Weight | Measures |
| --- | ---: | --- | ---: | --- |
| Quality | 46 | Average | 22% | Returns, margins, earnings quality |
| Valuation | 50 | Average | 24% | Cheap vs sector & own history |
| Growth | 24 | Poor | 9% | Sales & profit trajectory |
| Financial Health | 85 | Strong | 9% | Solvency, leverage, coverage |
| Momentum | 98 | Strong | 12% | Trend strength, vol-adjusted |
| Ownership | 51 | Average | 24% | FII/DII/promoter flows |

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

## Key Insights

### Strengths

- Company has reduced debt.
- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 66.6%

### Weaknesses

- The company has delivered a poor sales growth of -1.46% over past five years.
- Company has a low return on equity of 11.9% over last 3 years.
- Earnings include an other income of Rs.36.9 Cr.

## Technical Indicators

As of 4 Nov 2026.

| Group | Signal | Bearish | Neutral | Bullish |
| --- | --- | ---: | ---: | ---: |
| Overall | Bearish | 8 | 6 | 5 |
| Oscillators | Bearish | 2 | 6 | 1 |
| Moving Averages | Strong Bearish | 6 | 0 | 4 |

### Oscillators: Bearish

| Name | Value | Signal |
| --- | ---: | --- |
| RSI (14) | 40.33 | Neutral |
| MACD (12,26,9) | -51.59 | Bearish |
| Stochastic (14,3,3) | 23.52 | Neutral |
| ADX (14) | 25.98 | Bullish |
| Williams %R (14) | -70.33 | Neutral |
| ATR (14) | 111.50 | Neutral |
| ROC (12) | -9.66 | Bearish |
| Stoch RSI (14) | 38.42 | Neutral |
| UO (7,14,28) | 47.72 | Neutral |

### Moving Averages: Strong Bearish

| Name | Value | Signal |
| --- | ---: | --- |
| SMA (10) | 1,762.80 | Bearish |
| EMA (10) | 1,771.22 | Bearish |
| SMA (20) | 1,859.77 | Bearish |
| EMA (20) | 1,823.10 | Bearish |
| SMA (50) | 1,862.66 | Bearish |
| EMA (50) | 1,816.84 | Bearish |
| SMA (100) | 1,695.59 | Bullish |
| EMA (100) | 1,681.10 | Bullish |
| SMA (200) | 1,321.70 | Bullish |
| EMA (200) | 1,430.54 | Bullish |

### Pivot Points

| Level | Classic | Fibonacci | Camarilla |
| --- | ---: | ---: | ---: |
| R3 | 1,906.06 | 1,822.03 | 1,752.22 |
| R2 | 1,822.03 | 1,769.35 | 1,739.58 |
| R1 | 1,768.16 | 1,736.81 | 1,726.94 |
| PP | 1,684.13 | 1,684.13 | 1,684.13 |
| S1 | 1,630.26 | 1,631.45 | 1,701.66 |
| S2 | 1,546.23 | 1,598.91 | 1,689.02 |
| S3 | 1,492.36 | 1,546.23 | 1,676.38 |

## Growth Rate

Growth computed from the financial statements below. A window with no rate gives the reason instead of a figure.

| Metric | Window | Growth | What it compares |
| --- | --- | ---: | --- |
| Revenue | 10Y | -6.46% | compounded annual rate, Mar 2016 to Mar 2026 |
| Revenue | 5Y | -1.46% | compounded annual rate, Mar 2021 to Mar 2026 |
| Revenue | 3Y | -2.25% | compounded annual rate, Mar 2023 to Mar 2026 |
| Revenue | 1Y | -0.56% | fiscal year to Mar 2026 vs the year to Mar 2025 |
| Revenue | TTM | 5.4% | four quarters to Jun 2026 vs the four to Jun 2025 |
| Net profit | 10Y | -7.28% | compounded annual rate, Mar 2016 to Mar 2026 |
| Net profit | 5Y | 34.66% | compounded annual rate, Mar 2021 to Mar 2026 |
| Net profit | 3Y | -3.35% | compounded annual rate, Mar 2023 to Mar 2026 |
| Net profit | 1Y | -7.92% | fiscal year to Mar 2026 vs the year to Mar 2025 |
| Net profit | TTM | -4.9% | four quarters to Jun 2026 vs the four to Jun 2025 |
| Operating cash flow | 10Y | -1.91% | compounded annual rate, Mar 2016 to Mar 2026 |
| Operating cash flow | 5Y | Turned positive | compounded annual rate, Mar 2021 to Mar 2026: -₹69.00 Cr to ₹47.00 Cr. A cash outflow at the start and an inflow at the end. |
| Operating cash flow | 3Y | 1.46% | compounded annual rate, Mar 2023 to Mar 2026 |
| Operating cash flow | 1Y | -37.33% | fiscal year to Mar 2026 vs the year to Mar 2025 |
| Operating cash flow | TTM | — | four quarters to Jun 2026 vs the four to Jun 2025. Reported once a year, so there is no trailing-twelve-month figure. |
| Operating margin | 10Y | +21.62 pp | compounded annual rate, Mar 2016 to Mar 2026 |
| Operating margin | 5Y | +19.46 pp | compounded annual rate, Mar 2021 to Mar 2026 |
| Operating margin | 3Y | +9.40 pp | compounded annual rate, Mar 2023 to Mar 2026 |
| Operating margin | 1Y | +0.99 pp | fiscal year to Mar 2026 vs the year to Mar 2025 |
| Operating margin | TTM | +0.50 pp | four quarters to Jun 2026 vs the four to Jun 2025 |

## AI Analysis — Bull vs Bear

AI-generated opinion, based on fundamentals. Generated 31 Jul 2026. Not investment advice, and not a recommendation to buy, sell or hold. Statements that rate the stock or set a price target are left out of this copy.

- **Risk (AI assessment):** Medium

Novartis India Ltd is a nearly debt-free healthcare company with a market cap of Rs.3,933 Cr trading at a PE of 39.7x. The stock has delivered a 61% return over the past year despite underlying sales declining at -2% CAGR over 3 years and profit declining at -3% CAGR over the same period.

### Bull Case

- Company is virtually debt-free, providing strong balance sheet resilience and financial flexibility
- Stock has delivered 61% returns over the past 1 year, reflecting strong market re-rating
- 3-year stock CAGR of 29% significantly outpaces underlying earnings growth, indicating investor confidence in turnaround potential
- ROE has improved to 12% in the last year from a 10-year average of 8%, showing improving capital efficiency
- Dividend yield of 1.59% provides income support, relatively attractive for a healthcare company
- 5-year compounded profit CAGR of 35% indicates the company has delivered strong bottom-line expansion over the medium term
- Backed by global parent Novartis AG, providing access to a pipeline of patented therapies and operational expertise

### Bear Case

- Sales have declined at -2% CAGR over 3 years and -6% CAGR over 10 years, indicating a structurally shrinking revenue base
- TTM profit growth is negative at -5%, indicating near-term earnings deterioration
- ROE of 11.9% over 3 years is low for a pharma company with negligible debt, suggesting suboptimal capital deployment
- Other income of Rs.36.9 Cr forms a significant portion of earnings, meaning core operating profitability may be overstated
- 10-year compounded profit CAGR of -7% reflects long-term structural decline in earnings power
- Price-to-book ratio of 4.75x is high relative to the modest ROE of 12%, implying expensive valuation on asset basis
- TTM sales growth of just 5% after years of decline does not yet confirm a sustained revenue recovery

This is AI-generated analysis, not financial advice. Do your own due diligence.

## AI News Digest

AI-generated summary of recent news, generated 31 Jul 2026. Not investment advice, and not a recommendation to buy, sell or hold. Statements that rate the stock or set a price target are left out of this copy.

**TL;DR:** Novartis India has undergone a complete change of control, with ChrysCapital-led investors acquiring 70.68% from Novartis AG and reconstituting the board. The key forward-looking question is whether ChrysCapital's new management can unlock value through a refreshed strategy, though execution under new ownership remains uncertain.

### Positives

- **ChrysCapital acquires 70.68% stake** (Jul 29): WaveRise Investments, ChrysCapital Fund X, and Two Infinity Partners acquired a combined 70.68% stake in Novartis India Limited, as disclosed in a SEBI SAST filing on July 29, 2026.

### Neutral

- **Board reconstituted post takeover** (Jul 29): Novartis India's board was reconstituted on July 29, 2026, with six new directors appointed and six outgoing directors resigning following ChrysCapital's acquisition of control from Novartis AG.
- **Open offer sees minimal acceptance** (Jul 10): The open offer by WaveRise, ChrysCapital, and Two Infinity concluded with only 40 shares tendered at ₹860.64 per share, indicating existing shareholders largely preferred to hold their positions.

## Financial Statements

### Quarterly Results

Figures in ₹ crore unless the row name gives another unit.

| Item | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Sales | 91 | 79 | 85 | 81 | 92 | 87 | 93 | 84 | 88 | 90 | 86 | 91 | 104 |
| Expenses | 73 | 62 | 65 | 70 | 68 | 69 | 67 | 60 | 60 | 66 | 64 | 70 | 69 |
| Operating Profit | 17 | 17 | 20 | 11 | 24 | 18 | 26 | 24 | 27 | 24 | 22 | 21 | 35 |
| OPM % | 19% | 21% | 23% | 14% | 26% | 21% | 28% | 29% | 31% | 26% | 26% | 23% | 34% |
| Other Income | 12 | 17 | 22 | 10 | 10 | 10 | 11 | 11 | 11 | 9 | 9 | 10 | 9 |
| Interest | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Depreciation | 2 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 |
| Profit before tax | 28 | 32 | 41 | 21 | 34 | 28 | 35 | 34 | 37 | 33 | 30 | 30 | 43 |
| Tax % | 27% | 27% | 36% | 31% | 24% | 26% | 28% | 14% | 26% | 26% | 46% | 16% | 25% |
| Net Profit | 20 | 24 | 27 | 15 | 26 | 20 | 25 | 29 | 28 | 24 | 16 | 25 | 32 |
| EPS in Rs | 8.21 | 9.59 | 10.76 | 5.95 | 10.42 | 8.27 | 10.31 | 11.87 | 11.19 | 9.81 | 6.52 | 10.23 | 13.05 |

### Profit & Loss

Figures in ₹ crore unless the row name gives another unit.

| Item | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Sales | 870 | 690 | 656 | 564 | 491 | 438 | 381 | 400 | 379 | 335 | 356 | 354 | 371 |
| Expenses | 874 | 656 | 631 | 570 | 478 | 426 | 355 | 373 | 314 | 270 | 265 | 260 | 269 |
| Operating Profit | -4 | 34 | 25 | -6 | 12 | 12 | 27 | 27 | 65 | 65 | 91 | 94 | 102 |
| OPM % | -0.4% | 5% | 3.8% | -1.1% | 2.5% | 2.8% | 7% | 7% | 17% | 19% | 26% | 27% | 27% |
| Other Income | 101 | 207 | 71 | 172 | 78 | 36 | 33 | -17 | 58 | 62 | 42 | 39 | 37 |
| Interest | 0 | 0 | 1 | 6 | 2 | 6 | 8 | 5 | 2 | 1 | 1 | 1 | 1 |
| Depreciation | 4 | 3 | 4 | 3 | 3 | 13 | 12 | 10 | 6 | 3 | 2 | 2 | 2 |
| Profit before tax | 93 | 237 | 92 | 158 | 86 | 29 | 40 | -4 | 115 | 123 | 130 | 130 | 136 |
| Tax % | 15% | 16% | 38% | 50% | 40% | 65% | 48% | -3% | 10% | 31% | 23% | 28% | — |
| Net Profit | 79 | 198 | 57 | 78 | 52 | 10 | 21 | -4 | 103 | 85 | 101 | 93 | 98 |
| EPS in Rs | 24.75 | 62.04 | 20.33 | 31.74 | 20.97 | 4.08 | 8.46 | -1.51 | 41.86 | 34.5 | 40.87 | 37.74 | 39.61 |
| Dividend Payout % | 40% | 16% | 49% | 32% | 48% | 245% | 118% | n/m | 113% | 72% | 61% | 66% | — |

n/m: Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number.

### Balance Sheet

Figures in ₹ crore unless the row name gives another unit.

| Item | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Equity Capital | 16 | 16 | 14 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 |
| Reserves | 986 | 1,178 | 906 | 721 | 747 | 708 | 699 | 679 | 763 | 732 | 773 | 805 |
| Borrowings | 0 | 0 | 0 | 0 | 0 | 68 | 62 | 24 | 22 | 7 | 5 | 3 |
| Other Liabilities | 244 | 239 | 230 | 377 | 223 | 289 | 229 | 242 | 186 | 173 | 158 | 157 |
| Total Liabilities | 1,246 | 1,433 | 1,150 | 1,111 | 982 | 1,078 | 1,002 | 958 | 983 | 925 | 948 | 978 |
| Fixed Assets | 8 | 6 | 6 | 5 | 15 | 76 | 64 | 24 | 19 | 7 | 5 | 3 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 1,238 | 1,426 | 1,144 | 1,106 | 967 | 1,001 | 938 | 934 | 964 | 918 | 943 | 975 |
| Total Assets | 1,246 | 1,433 | 1,150 | 1,111 | 982 | 1,078 | 1,002 | 958 | 983 | 925 | 948 | 978 |

### Cash Flow

Figures in ₹ crore unless the row name gives another unit.

| Item | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash from Operating Activity | -60 | 57 | -41 | 161 | -194 | -23 | -69 | 39 | 45 | 113 | 75 | 47 |
| Cash from Investing Activity | 719 | -630 | 424 | 69 | 274 | 56 | 95 | 87 | -153 | 33 | -3 | 18 |
| Cash from Financing Activity | -38 | -39 | -332 | -268 | -30 | -41 | -37 | -36 | -30 | -121 | -64 | -64 |
| Net Cash Flow | 622 | -612 | 51 | -38 | 50 | -9 | -11 | 90 | -139 | 26 | 7 | 0 |
| Free Cash Flow | -64 | 54 | -44 | 160 | -208 | -24 | -69 | 38 | 45 | 113 | 75 | 46 |
| CFO/EBITDA | 601 | 398 | 13 | -3,503 | -1,210 | 124 | -127 | 210 | 65 | 115 | 99 | 87 |

### Ratios

| Item | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Debtor Days | 35 | 27 | 23 | 28 | 34 | 31 | 37 | 41 | 35 | 45 | 41 | 38 |
| Inventory Days | 103 | 92 | 104 | 84 | 111 | 117 | 119 | 117 | 99 | 82 | 74 | 98 |
| Days Payable | 98 | 89 | 87 | 158 | 168 | 145 | 137 | 148 | 108 | 112 | 93 | 101 |
| Cash Conversion Cycle | 40 | 30 | 40 | -45 | -23 | 3 | 19 | 10 | 26 | 15 | 22 | 36 |
| Working Capital Days | 6 | -35 | -14 | -99 | 7 | -1 | 62 | -23 | -37 | -59 | -45 | -46 |
| ROCE % | 9% | 22% | 9% | 17% | 12% | 5% | 6% | 6% | 15% | 16% | 17% | 16% |

## Shareholding Pattern

### Quarterly Shareholding

Holdings in % of shares; shareholders as a count.

| Holder | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Promoters | 70.68% | 70.68% | 70.68% | 70.68% | 70.68% | 70.68% | 70.68% | 70.68% | 70.68% | 70.68% | 70.68% | 70.68% | 70.68% | 70.68% | 70.68% | 70.68% | 70.68% | 70.68% | 70.68% | 70.68% | 70.68% | 70.68% | 70.68% |
| FIIs | 0.06% | 0.06% | 0.03% | 0.09% | 0.12% | 0.14% | 0.17% | 0.17% | 0.17% | 0.24% | 0.32% | 0.19% | 0.19% | 0.19% | 0.19% | 0.19% | 0.19% | 0.19% | 0.19% | 0.19% | 0.17% | 0.16% | 1.22% |
| DIIs | 0.78% | 0.84% | 0.78% | 0.78% | 0.77% | 0.78% | 0.79% | 0.79% | 0.79% | 0.76% | 0.53% | 0.53% | 0.53% | 0.53% | 0.53% | 0.53% | 0.53% | 0.53% | 0.53% | 0.64% | 0.53% | 1.36% | 1.50% |
| Government | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public | 23.34% | 23.03% | 23.09% | 22.98% | 22.88% | 22.94% | 23.02% | 23.01% | 23.03% | 23.08% | 23.29% | 23.21% | 22.95% | 23.04% | 23.05% | 23.01% | 23.11% | 22.95% | 22.92% | 22.67% | 23.25% | 22.50% | 21.29% |
| Others | 5.20% | 5.46% | 5.45% | 5.56% | 5.66% | 5.60% | 5.52% | 5.52% | 5.51% | 5.48% | 5.18% | 5.39% | 5.65% | 5.57% | 5.55% | 5.59% | 5.49% | 5.66% | 5.68% | 5.83% | 5.36% | 5.31% | 5.31% |
| No. of Shareholders | 41,572 | 43,784 | 45,141 | 44,640 | 44,370 | 43,996 | 43,275 | 42,622 | 41,947 | 43,343 | 43,992 | 43,128 | 41,239 | 39,265 | 39,596 | 38,926 | 39,133 | 39,040 | 39,353 | 39,468 | 38,116 | 36,502 | 38,127 |

## Documents

### Concalls

| Month | Call documents |
| --- | --- |
| Sep 2026 | [Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b22bd8a0-667d-40ce-8434-fb4bbc89f050.pdf), [PPT](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=47144cbd-96be-46eb-9d97-444a8c3ea19d.pdf), [Recording](https://nilpharma.co.in/pdfs/investors/sed/Analyst_Call_Audio%20_Recording.mp3) |

### Results

Latest 12 of 36.

| Date | Document |
| --- | --- |
| 4 Nov 2026 | [Intimation Of The Integrated Unaudited Financial Results For The Quarter And Half Year Ended September 30 2026.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=21d91efe-8d62-4535-89ee-ff48cd72c236.pdf) |
| 3 Nov 2026 | [Unaudited Financial Results For The Quarter And Half Year Ended As On September 30 2026.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a57b4a67-e392-47fb-a2be-568e17eb6fb3.pdf) |
| 23 Jul 2026 | [Financial Results Of Novartis India Limited For The Quarter Ended June 30 2026.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=155fb5bd-acc7-4f62-b613-9ab3e5ae241e.pdf) |
| 12 May 2026 | [Integrated Financial Results For The Quarter And Financial Year Ended March 31 2026.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8e743d4b-904a-4fc8-80c8-881e9e32a863.pdf) |
| 28 Jan 2026 | [Integrated Filing (Financial) For The Quarter Ended December 31 2025.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=bcbcb00e-9aa6-4e62-a609-aa0914ade777.pdf) |
| 28 Oct 2025 | [Integrated Unaudited Financial Results And Limited Review Report For The Quarter And Half-Year Ended September 30 2025.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=06eda567-07be-42ce-920f-f90cabaad4a7.pdf) |
| 29 Jul 2025 | [Unaudited Financial Results For The Quarter Ended As On June 30 2025.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2b0c7bfd-e2c1-4755-8663-2d2e83f5a238.pdf) |
| 9 May 2025 | [Financial Results For The Quarter And Year Ended As On March 31 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d3d25b0d-74c4-4a61-93f7-3d1935195d3a.pdf) |
| 28 Jan 2025 | [Filing Of Unaudited Financial Results And Limited Review Report For The Quarter And Nine Months Ended December 31 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6bab3dbe-22fa-4099-a83f-1cb2f8e76996.pdf) |
| 25 Oct 2024 | [Filing Of The Outcome Of Board Meeting And Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a6577711-ef26-4348-b849-5d845d909221.pdf) |
| 29 Jul 2024 | [Outcome - Unaudited Financial Results For The Quarter Ended June 30, 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=179c1dd7-8cb6-432f-8f21-5337569dbcbd.pdf) |
| 29 Jul 2024 | [Results - Unaudited Financial Results For The First Quarter Ended June 30, 2024.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d07197a8-a5e5-49b0-8b7b-9b100741c5f0.pdf) |

### Annual reports

Latest 12 of 16.

| Year | Report |
| --- | --- |
| FY2026 | [Annual report](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0ae7a09e-cbe6-4842-8196-329748e70ea3.pdf) |
| FY2025 | [Annual report](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4ca2b229-36f0-4585-9c8e-5e0d077304c4.pdf) |
| FY2024 | [Annual report](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9b0205b9-16fe-4d7a-804f-d67959700767.pdf) |
| FY2023 | [Annual report](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b415137f-f341-406c-ad13-6aa820190ca1.pdf) |
| FY2022 | [Annual report](https://www.bseindia.com/bseplus/AnnualReport/500672/73362500672.pdf) |
| FY2021 | [Annual report](https://www.bseindia.com/bseplus/AnnualReport/500672/69195500672.pdf) |
| FY2020 | [Annual report](https://www.bseindia.com/bseplus/AnnualReport/500672/5006720320.pdf) |
| FY2019 | [Annual report](https://www.bseindia.com/bseplus/AnnualReport/500672/5006720319.pdf) |
| FY2018 | [Annual report](https://www.bseindia.com/bseplus/AnnualReport/500672/5006720318.pdf) |
| FY2017 | [Annual report](https://www.bseindia.com/bseplus/AnnualReport/500672/5006720317.pdf) |
| FY2016 | [Annual report](https://www.bseindia.com/bseplus/AnnualReport/500672/5006720316.pdf) |
| FY2015 | [Annual report](https://www.bseindia.com/bseplus/AnnualReport/500672/5006720315.pdf) |

### Exchange filings

Latest 12 of 114.

| Date | Document | Category |
| --- | --- | --- |
| 3 Nov 2026 | [Board Meeting Outcome for Intimation Of The Unaudited Financial Results Along With The Limited Review Report For The Quarter And Half Year Ended September 30 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e6d39622-58d9-4c73-afe0-8d7bb5d2a297.pdf) | Outcome |
| 3 Nov 2026 | [Announcement under Regulation 30 (LODR)-Press Release / Media Release](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4933df8d-8454-4c1e-b292-2e323c5f3d3e.pdf) | General announcements |
| 3 Nov 2026 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3b6c14a5-4a02-43ff-ad7a-a6af35399083.pdf) | — |
| 1 Nov 2026 | [Board Meeting Intimation for Approval Of The Letter Of Offer And Intimation Of The Rights Issue Committee Meeting To Decide And Discuss Matters In Connection With The Rights Issue.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=328631a5-317e-4358-96d6-c6d09f2d91ea.pdf) | Intimation |
| 1 Nov 2026 | [Disclosure Of The Receipt Of In-Principle Approval From The Stock Exchange I.E. BSE Limited In Relation To The Draft Letter Of Offer.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6d54cd11-3469-4231-beef-51e0f29e07c0.pdf) | General announcements |
| 26 Oct 2026 | [Announcement under Regulation 30 (LODR)-Change in Management](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1e998876-a28e-4e14-808d-05ad2c15dfb2.pdf) | General announcements |
| 26 Oct 2026 | [Intimation Of The Earnings Call Proposed To Be Held On November 04 2026 At 02:30 PM IST](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=447218aa-2f89-4b85-8a6c-249f05530c23.pdf) | General announcements |
| 14 Oct 2026 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a816de80-6c5f-4917-916b-d63f61a46e95.pdf) | General announcements |
| 13 Oct 2026 | [Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1983c281-838a-4d0d-a112-aba0b4b08b5e.pdf) | General announcements |
| 13 Oct 2026 | [Notice Of Postal Ballot (02/2026-27) - Disclosure Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 (Listing Regulations) Of Evonile Pharma Limited (Formerly Known As Novar](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=626bfb51-f2d0-4713-81dd-a49bb1a51f2b.pdf) | General announcements |
| 8 Oct 2026 | [Board Meeting Outcome for Intimation Of The Outcome Of The Board Meeting Held Today Dated October 08 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b9817b51-0b78-4d23-9c13-3f23bce27fc3.pdf) | Outcome |
| 8 Oct 2026 | [Announcement under Regulation 30 (LODR)-Issue of Securities](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d6b79094-622e-45f0-9ee8-a34c53a26e62.pdf) | General announcements |

## Frequently Asked Questions about Novartis

### What does Novartis India Ltd do?

Novartis India Ltd is primarily engaged in the Business of Wholesale of pharmaceuticals and medical goods. It imports various medicines to India from different sources across the globe.

### Where is Novartis India Ltd (EVONILE) listed?

Novartis India Ltd trades as EVONILE on the NSE and under code 500672 on the BSE.

### Which sector does Novartis India Ltd belong to?

Novartis India Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.

### What is the PE ratio of Novartis India Ltd?

Novartis India Ltd trades at a PE ratio of 43.28 as of 4 Nov 2026, on earnings per share of ₹39.61, against a book value of ₹331.23 per share.

### What is the 52-week high and low of Novartis India Ltd?

Over the last 52 weeks Novartis India Ltd has traded between ₹909.7 and ₹2,588.8 as of 4 Nov 2026.

### Does Novartis India Ltd pay dividends?

Novartis India Ltd has a dividend yield of 1.45%.

### What is the Return on Equity (ROE) of Novartis India Ltd?

Novartis India Ltd reported a return on equity of 11.60%. Its debt-to-equity ratio is 0.00.

## Company Information

Novartis India Ltd is primarily engaged in the Business of Wholesale of pharmaceuticals and medical goods. It imports various medicines to India from different sources across the globe.

- **Website:** https://novartis.in/
- **CEO:** Ms. Shilpa Shashank Joshi
- **Employees:** 56
- **Listed:** 20 Apr 2026
- **Face Value:** ₹5

---

Negative figures use an ASCII hyphen-minus (-) so they parse as numbers. Amounts are in Indian rupees; "Cr" is crore (10 million). Dates are Indian Standard Time.

Financial statements, shareholding and filings are as reported by the company. Price, volume and 52-week levels are market data. Technical indicators are computed by Tapetide from daily prices. The Tapetide Score is Tapetide’s own analysis. Analyst ratings and forecasts are the published estimates of third-party analysts, not company statements. The AI sections are generated text.

For research and information only, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Generated 5 Nov 2026, 07:04 IST.